Background: The introduction of new therapies has made it important to differentiate between adenocarcinoma and squamous cell carcinoma. To allow the use of various immunocytochemical stains on limited materials, we tried transferring cells from a given smear to multiple slides. Using touch-preparation samples of 215 surgically resected non-small cell lung carcinomas of confirmed histologic classification (adenocarcinoma,n = 101; squamous cell carcinoma,n = 114), we performed immunocytochemistry for thyroid transcription factor-1, napsin A, p40, p63, CK5/6 and desmocollin-3, and compared cytologic staining results with the corresponding resection. Methods: We examined: (a) the expressions of the above 6 antibodies on cells transferred from touch imprints of resected specimens, the extent of staining being considered positive if more than 5% of the area was stained, and (b) the sensitivity, specificity, positive predictive value and negative predictive value for each antibody. Results: The histologic corresponding rate with Papanicolaou staining was only 73%. Regarding the differentiation of adenocarcinoma from squamous cell carcinoma, the sensitivity and specificity for napsin A in adenocarcinoma were 80 and 97%, respectively, while those for p40 in squamous cell carcinoma were 84 and 98%, respectively. Conclusion: The immunocytochemical expressions of napsin A and p40 in imprint cytology seem to be of great utility for the accurate histological differentiation of lung cancers.

1.
Statistics and Information Department: Vital Statistics of Japan 2013/2014. Tokyo, Ministry of Health, Labour and Welfare, 2013/2014, pp 59-60.
2.
Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
3.
Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
4.
Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
5.
Travis WD, Brambilla E, Noguchi M, et al: The new IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
6.
Edwards SL, Roberts C, McKean ME, et al: Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000;53:537-540.
7.
Rekhtman N, Brandt SM, Sigel CS, et al: Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011;6:451-458.
8.
Sigel CS, Moreira AL, Travis WD, et al: Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol 2011;6:1849-1856.
9.
Nicholson AG, Gonzalez D, Shah P: Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010;5:436-441.
10.
Au NHC, Gown AM, Cheang M, et al: p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004;12:240-247.
11.
Mukhopadhyay S, Katzenstein AL: Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25.
12.
Fatima N, Cohen C, Lawson D, et al: TTF-1 and napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol 2011;119:127-133.
13.
Travis W, Brambilla E, Müller-Hermelink H, Harris C (eds): World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004, pp 9-67.
14.
Sherman ME, Jimenez-Joseph D, Gangi MD, et al: Immunostaining of small cytologic specimens: facilitation with cell transfer. Acta Cytol 1994;38:18-22.
15.
Gong Y, Joseph T, Sneige N: Validation of commonly used immunostains on cell-transferred cytologic specimens. Cancer 2005;105:158-164.
16.
Kawai T, Hiroi S, Nakanishi K, et al: Lymphohistiocytoid mesothelioma of the pleura. Pathol Int 2010;60:566-574.
17.
Marshall AE, Cramer HM, Wu HH: The usefulness of the cell transfer technique for immunocytochemistry of fine-needle aspirates. Cancer Cytopathol 2014;122:898-902.
18.
Shabaik A, Lin G, Peterson M, et al: Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol 2010;39:328-332.
19.
Nakazato Y, Minami Y, Kobayashi H, et al: Nuclear grading of primary pulmonary adenocarcinomas. Cancer 2010;116:2011-2019.
20.
Sigel CS, Rudomina DE, Sima CS, et al: Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. Cancer Cytopathol 2012;120:35-43.
21.
Ordóñez NG: Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol 2000;7:123-127.
22.
Ordóñez NG: Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.
23.
Hecht JL, Pinkus JL, Weinstein LJ, et al: The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol 2001;116:483-488.
24.
Afify AM, al-Khafaji BM: Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol 2002;46:675-678.
25.
Dejmek A, Naucler P, Smedjeback A, et al: Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol 2007;35:493-497.
26.
Ocque R, Tochigi N, Ohori NP, et al: Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. Am J Clin Pathol 2011;136:81-87.
27.
Tatnell PJ, Powell DJ, Hilla J, et al: Napsins: new human aspartic proteinases: distinction between two closely related genes. FEBS Lett 1998;441:43-48.
28.
Chuman Y, Bergman AC, Ueno T, et al: Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999;462:129-134.
29.
Schauer-Vukasinovic V, Bur D, Kling D, et al: Human napsin A: expression, immunochemical detection, and tissue localization. FEBS Lett 1999;462:135-139.
30.
Hirano T, Auer G, Maeda M, et al: Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A. Jpn J Cancer Res 2000;91:1015-1021.
31.
Hirano T, Gong Y, Yoshida K, et al: Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003;41:155-162.
32.
Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010;41:20-25.
33.
Yamashita Y, Nagasaka T, Naiki-Ito A, et al: Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod Pathol 2015;28:111-117.
34.
Ueno T, Linder S, Elmberger G: Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 2003;88:1229-1233.
35.
Stoll LM, Johnson MW, Gabrielson E, et al: The utility of Napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer 2010;118:441-449.
36.
Wang BY, Gil J, Kaufman D, et al: p63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 2001;33:921-926.
37.
Pelosi G, Pasisni F, Olsen Stenholm C, et al: p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 2002;198:100-109.
38.
Shtilbans V, Szporn AH, Wu M, et al: p63 immunostaining in destained bronchoscopic cytological specimens. Diagn Cytopathol 2005;32:198-203.
39.
Kalhor N, Zander DS, Liu J: TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously Pap-stained cytologic material. Mod Pathol 2006;19:1117-1123.
40.
Jorda M, Gomez-Fernandez C, Garcia M, et al: P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer 2009;117:46-50.
41.
Khayyata S, Yun S, Pasha T, et al: Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009;37:178-183.
42.
Ordóñez NG: Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-1221.
43.
Chu PG, Weiss LM: Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002;15:6-10.
44.
Jerome Marson V, Mazieres J, Groussard O, et al: Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology 2004;45:125-134.
45.
Kargi A, Gurel D, Tuna B: The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007;15:415-420.
46.
Tsuta K, Tanabe Y, Yoshida A, et al: Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. J Thorac Oncol 2011;6:1190-1199.
47.
Warth A, Muley T, Herpel E, et al: Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathol 2012;61:1017-1025.
48.
Pu RT, Pang Y, Michael CW: Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol 2008;36:20-25.
49.
Collins BT, Wang JF, Bernadt CT: Utilization of p40 (ΔNp63) with p63 and cytokeratin 5/6 immunohistochemistry in non-small cell lung carcinoma fine-needle aspiration biopsy. Acta Cytol 2013;57:619-624.
50.
Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al: Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008;214:347-356.
51.
Monica V, Ceppi P, Righi L, et al: Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 2009;22:709-717.
52.
Crum CP, McKeon FD: p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 2010;5:349-371.
53.
Bishop JA, Teruya-Feldstein J, Westra WH, et al: p40 (DNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012;25:405-415.
54.
Nylander K, Vojtesek B, Nenutil R, et al: Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417-427.
55.
Hibi K, Trink B, Patturajan M, et al: AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000;97:5462-5467.
56.
Geddert H, Kiel S, Heep HJ, et al: The role of p63 and ΔNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum Pathol 2003;34:850-856.
57.
Chilosi M, Zamo A, Brighenti A, et al: Constitutive expression of ΔN-p63α isoform in human thymus and thymic epithelial tumours. Virchows Archiv 2003;443:175-183.
58.
Karni-Schmidt O, Castillo-Martin M, Shen TH, et al: Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2010;178:1350-1360.
59.
Righi L, Graziano P, Fornari A, et al: Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology. Cancer 2011;117:3416-3423.
60.
Pelosi G, Fabbri A, Bianchi F, et al: ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 2012;7:281-290.
61.
Jain D, Mathur SR, Guleria R, et al: Utility and pattern of positivity of p40 in the diagnosis of squamous cell carcinoma of the lung by cytology: the first study on fine needle aspiration smears. Cytopathology 2014;25:330-335.
62.
Zhang Y, Sun Y, Pan Y, et al: Frequency in lung adenocarcinoma from female never-smoker varies with histological subtypes and age at diagnosis. Clin Cancer Res 2012;18:1947-1953.
63.
Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-515.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.